Analysis of pre-chemotherapy plasma ANGPT1 and TIE-2 expression from patients participating in an ovarian cancer trial, randomized to conventional dose Carboplatin and Paclitaxel ± Bevacizumab is described by Backen et al., [49]. The gene discussed is TIE1; the disease is ovarian carcinoma.